XTX Topco’s Apellis Pharmaceuticals APLS Stock Holding History

XTX Topco’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-41,627	Closed	-$1.67M	–	4130
2026 Q1	$1.67M	Buy	+41,627	New	+$897K	0.03%	977
2025 Q4	–	Sell	-14,407	Closed	-$326K	–	3293
2025 Q3	$326K	Buy	+14,407	New	+$336K	0.02%	1444
2025 Q1	–	Sell	-9,785	Closed	-$312K	–	2381
2024 Q4	$312K	Buy	9,785 +2,649	+37%	+$79.7K	0.03%	1184
2024 Q3	$206K	Buy	+7,136	New	+$264K	0.01%	1436
2024 Q2	–	Sell	-5,440	Closed	-$320K	–	1838
2024 Q1	$320K	Buy	+5,440	New	+$347K	0.04%	798
2023 Q4	–	Sell	-12,796	Closed	-$487K	–	1564
2023 Q3	$487K	Buy	+12,796	New	+$562K	0.08%	420
2022 Q2	–	Sell	-5,422	Closed	-$275K	–	837
2022 Q1	$275K	Buy	+5,422	New	+$239K	0.12%	298

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

XTX Topco's APLS Position: Q2 2026 in Review

XTX Topco sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 41,627 shares — an estimated $1.67M sold.

XTX Topco first reported a position in APLS in Q1 2022 and held it in 7 quarters. The position peaked at $1.67M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

XTX Topco reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 41,627 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.67M.
XTX Topco first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 7 quarters.
XTX Topco's Apellis Pharmaceuticals position peaked at $1.67M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.